TY  - JOUR
AU  - Gómez Almería, Marta
AU  - Martinez Gonzalez, Loreto
AU  - Matos, Ana Teresa
AU  - Rodríguez Cueto, Carmen Aurora
AU  - Vaz, Ana Rita
AU  - Martín Baquero, Raquel
AU  - Pérez de la Lastra, Carmen
AU  - Infantes, Rafael
AU  - Fernández Ruiz, José Javier
AU  - Palomo, Valle
AU  - Gil, Carmen
AU  - Brites, Dora
AU  - Martinez, Ana
AU  - Lago Femia, Eva De
PY  - 2025
DO  - 10.1016/j.neuropharm.2025.110804
SN  - 0028-3908
UR  - https://hdl.handle.net/20.500.14352/131162
T2  - Neuropharmacology
AB  - Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease for which no effective treatments currently exist. The FDA and EMA have approved only riluzole, a drug that modestly extends patient survival by 3-18 months. In our...
LA  - eng
PB  - Elsevier
KW  - Amyotrophic lateral sclerosis
KW  - Neuroinflammation
KW  - Neuroprotection
KW  - miRNAs
KW  - Protein kinase inhibitor
KW  - Riluzole
KW  - Combinatory therapy
KW  - TDP-43
TI  - Assessment of the therapeutic effect ofigs2.7, a ck1δ protein kinase inhibitor, in combination with riluzole for the treatment of als-associated tdp-43 proteinopathy
TY  - journal article
VL  - 285
ER  -